S&P 500   3,294.06 (+0.70%)
DOW   26,639.13 (+0.80%)
QQQ   269.10 (+1.25%)
AAPL   438.25 (+3.11%)
MSFT   212.36 (+3.59%)
FB   251.51 (-0.85%)
GOOGL   1,472.23 (-1.06%)
AMZN   3,124.63 (-1.27%)
NVDA   435.41 (+2.55%)
CGC   18.36 (+0.44%)
BABA   258.65 (+3.04%)
TSLA   1,485.73 (+3.84%)
MU   50.21 (+0.30%)
GE   6.12 (+0.82%)
AMD   77.88 (+0.58%)
T   29.61 (+0.10%)
F   6.62 (+0.15%)
ACB   9.89 (-2.94%)
GILD   71.30 (+2.55%)
NFLX   495.24 (+1.30%)
DIS   116.37 (-0.49%)
BAC   25.03 (+0.60%)
BA   157.18 (-0.52%)
S&P 500   3,294.06 (+0.70%)
DOW   26,639.13 (+0.80%)
QQQ   269.10 (+1.25%)
AAPL   438.25 (+3.11%)
MSFT   212.36 (+3.59%)
FB   251.51 (-0.85%)
GOOGL   1,472.23 (-1.06%)
AMZN   3,124.63 (-1.27%)
NVDA   435.41 (+2.55%)
CGC   18.36 (+0.44%)
BABA   258.65 (+3.04%)
TSLA   1,485.73 (+3.84%)
MU   50.21 (+0.30%)
GE   6.12 (+0.82%)
AMD   77.88 (+0.58%)
T   29.61 (+0.10%)
F   6.62 (+0.15%)
ACB   9.89 (-2.94%)
GILD   71.30 (+2.55%)
NFLX   495.24 (+1.30%)
DIS   116.37 (-0.49%)
BAC   25.03 (+0.60%)
BA   157.18 (-0.52%)
S&P 500   3,294.06 (+0.70%)
DOW   26,639.13 (+0.80%)
QQQ   269.10 (+1.25%)
AAPL   438.25 (+3.11%)
MSFT   212.36 (+3.59%)
FB   251.51 (-0.85%)
GOOGL   1,472.23 (-1.06%)
AMZN   3,124.63 (-1.27%)
NVDA   435.41 (+2.55%)
CGC   18.36 (+0.44%)
BABA   258.65 (+3.04%)
TSLA   1,485.73 (+3.84%)
MU   50.21 (+0.30%)
GE   6.12 (+0.82%)
AMD   77.88 (+0.58%)
T   29.61 (+0.10%)
F   6.62 (+0.15%)
ACB   9.89 (-2.94%)
GILD   71.30 (+2.55%)
NFLX   495.24 (+1.30%)
DIS   116.37 (-0.49%)
BAC   25.03 (+0.60%)
BA   157.18 (-0.52%)
S&P 500   3,294.06 (+0.70%)
DOW   26,639.13 (+0.80%)
QQQ   269.10 (+1.25%)
AAPL   438.25 (+3.11%)
MSFT   212.36 (+3.59%)
FB   251.51 (-0.85%)
GOOGL   1,472.23 (-1.06%)
AMZN   3,124.63 (-1.27%)
NVDA   435.41 (+2.55%)
CGC   18.36 (+0.44%)
BABA   258.65 (+3.04%)
TSLA   1,485.73 (+3.84%)
MU   50.21 (+0.30%)
GE   6.12 (+0.82%)
AMD   77.88 (+0.58%)
T   29.61 (+0.10%)
F   6.62 (+0.15%)
ACB   9.89 (-2.94%)
GILD   71.30 (+2.55%)
NFLX   495.24 (+1.30%)
DIS   116.37 (-0.49%)
BAC   25.03 (+0.60%)
BA   157.18 (-0.52%)
Log in

NASDAQ:ORMPOramed Pharmaceuticals Stock Price, Forecast & News

$3.71
+0.04 (+1.09 %)
(As of 08/3/2020 11:20 AM ET)
Add
Compare
Today's Range
$3.71
Now: $3.71
$3.71
50-Day Range
$3.33
MA: $3.79
$4.16
52-Week Range
$2.32
Now: $3.71
$6.05
Volume100 shs
Average Volume125,683 shs
Market Capitalization$87.30 million
P/E RatioN/A
Dividend YieldN/A
Beta1.59
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule for the treatment of diabetes; and ORMD-0901, an oral glucagon-like peptide-1 analog capsule for the treatment of type 2 diabetes. It is also developing a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.
Read More
Oramed Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.45 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ORMP
CUSIPN/A
Phone844-967-2633

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.70 million
Cash Flow$0.84 per share
Book Value$1.12 per share

Profitability

Net Income$-14,350,000.00
Net Margins-230.07%

Miscellaneous

EmployeesN/A
Market Cap$87.30 million
Next Earnings Date11/25/2020 (Estimated)
OptionableOptionable
$3.71
+0.04 (+1.09 %)
(As of 08/3/2020 11:20 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ORMP News and Ratings via Email

Sign-up to receive the latest news and ratings for ORMP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Oramed Pharmaceuticals (NASDAQ:ORMP) Frequently Asked Questions

How has Oramed Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Oramed Pharmaceuticals' stock was trading at $3.31 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ORMP shares have increased by 12.1% and is now trading at $3.71.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Oramed Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oramed Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Oramed Pharmaceuticals
.

When is Oramed Pharmaceuticals' next earnings date?

Oramed Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, November 25th 2020.
View our earnings forecast for Oramed Pharmaceuticals
.

How were Oramed Pharmaceuticals' earnings last quarter?

Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) released its earnings results on Tuesday, July, 7th. The biotechnology company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.07. The biotechnology company had revenue of $0.68 million for the quarter, compared to the consensus estimate of $0.69 million. Oramed Pharmaceuticals had a negative return on equity of 28.75% and a negative net margin of 230.07%.
View Oramed Pharmaceuticals' earnings history
.

What price target have analysts set for ORMP?

3 brokers have issued twelve-month target prices for Oramed Pharmaceuticals' shares. Their forecasts range from $5.50 to $17.00. On average, they expect Oramed Pharmaceuticals' share price to reach $9.83 in the next twelve months. This suggests a possible upside of 165.0% from the stock's current price.
View analysts' price targets for Oramed Pharmaceuticals
.

Has Oramed Pharmaceuticals been receiving favorable news coverage?

News headlines about ORMP stock have been trending negative this week, InfoTrie reports. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Oramed Pharmaceuticals earned a daily sentiment score of -2.9 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the next few days.
View the latest news about Oramed Pharmaceuticals
.

Who are some of Oramed Pharmaceuticals' key competitors?

What other stocks do shareholders of Oramed Pharmaceuticals own?

Who are Oramed Pharmaceuticals' key executives?

Oramed Pharmaceuticals' management team includes the following people:
  • Mr. Nadav Kidron, CEO, Pres & Exec. Director (Age 45)
  • Dr. Miriam Kidron, Chief Scientific Officer, Chief Medical & Technology Officer and Director (Age 79)
  • Ms. Hilla Eisenberg CPA, CFO, Treasurer & Sec. (Age 35)
  • Dr. Roy Eldor M.D., Ph.D., Chief Medical Advisor & Member of the Scientific Advisory Board

What is Oramed Pharmaceuticals' stock symbol?

Oramed Pharmaceuticals trades on the NASDAQ under the ticker symbol "ORMP."

How do I buy shares of Oramed Pharmaceuticals?

Shares of ORMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Oramed Pharmaceuticals' stock price today?

One share of ORMP stock can currently be purchased for approximately $3.71.

How big of a company is Oramed Pharmaceuticals?

Oramed Pharmaceuticals has a market capitalization of $87.30 million and generates $2.70 million in revenue each year. The biotechnology company earns $-14,350,000.00 in net income (profit) each year or $0.82 on an earnings per share basis.

What is Oramed Pharmaceuticals' official website?

The official website for Oramed Pharmaceuticals is www.oramed.com.

How can I contact Oramed Pharmaceuticals?

Oramed Pharmaceuticals' mailing address is 1185 AVENUE SUITE 228, NEW YORK NY, 10036. The biotechnology company can be reached via phone at 844-967-2633 or via email at [email protected]

This page was last updated on 8/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.